Baxter wins FDA approval for renal therapy solution

SHARE Baxter wins FDA approval for renal therapy solution

A Baxter International Inc. product for use in renal replacement therapy has received approval from the U.S. Food and Drug Administration.

Baxter’s Phoxillum is designed to correct electrolyte and acid-base imbalances for patients undergoing continuous renal replacement therapy. The Deerfield pharmaceutical and medical device maker said it expects the product be available in the U.S. beginning in the second quarter.

“The approval of Phoxillum allows us to offer healthcare providers additional options in managing critically ill acute kidney injury patients treated with CRRT,” said Bruce Culleton, a Baxter vice president and head of its renal therapeutic area.

The Latest
The man was found unresponsive in an alley in the 10700 block of South Lowe Avenue, police said.
The man suffered head trauma and was pronounced dead at University of Chicago Medical Center, police said.
Another federal judge in Chicago who also has dismissed gun cases based on the same Supreme Court ruling says the high court’s decision in what’s known as the Bruen case will “inevitably lead to more gun violence, more dead citizens and more devastated communities.”
Women make up just 10% of those in careers such as green infrastructure and clean and renewable energy, a leader from Openlands writes. Apprenticeships and other training opportunities are some of the ways to get more women into this growing job sector.
Chatterbox doesn’t seem aware that it’s courteous to ask questions, seek others’ opinions.